TICKERNERD
Menu
HYPRHealthcare · Medical Devices

HYPR Stock Forecast: Hyperfine, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.79
+0.08% on the day

The 3 Wall Street analysts covering Hyperfine, Inc. hold a median 12-month price target of $2 — +154.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$83.4M
Ticker Nerd rank
50 / 100
Median analyst target
$2.00
Analysts covering
3
Revenue$3.9M+44.8% y/y
Operating income−$8.5M
Net income−$9.3M
Free cash flow−$7.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.0%
1M
−18.6%
YTD
−19.7%
1Y
−41.7%
From 52W high
−64.2%
From 52W low
+0.1%
$0.79
$2.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HYPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hyperfine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Revisions
88
Size
77
Accruals
57
Volatility
41
Quality
33
Value
22
Momentum
21
Issuance
9

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HYPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HYPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50Oct 25Jan 26Apr 26Jul 26HYPRHigh $2.50Median $2.00Low $1.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $1.60Median $2.00High $2.50

The green dot is the last close — the median target sits +154.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026B. Riley SecuritiesReiteratesBuy$2.00 → $1.60
29 Apr 2026BTIGInitiatesBuy$2.00
29 Apr 2026BTIGInitiatesBuy—
19 Mar 2026Lake StreetMaintainsBuy—
15 Aug 2025Wells FargoMaintainsEqual-Weight—
14 Aug 2025Lake StreetMaintainsBuy—
15 May 2025B. Riley SecuritiesMaintainsBuy—
14 May 2025Wells FargoMaintainsEqual-Weight—
24 Mar 2025Lake StreetInitiatesBuy—
20 Mar 2025B. Riley SecuritiesMaintainsBuy—
18 Mar 2025Wells FargoMaintainsEqual-Weight—
22 Mar 2024Wells FargoMaintainsEqual-Weight—
30 Nov 2023JefferiesInitiatesHold—
15 Aug 2023B. Riley SecuritiesMaintainsBuy—
22 Mar 2023B. Riley SecuritiesMaintainsBuy—
4 Oct 2022B. Riley SecuritiesInitiatesBuy—
11 Aug 2022Wells FargoDowngradeEqual-Weight—
31 May 2022Evercore ISI GroupInitiatesOutperform—
14 Apr 2022Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HYPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HYPR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Hyperfine, Inc. returned −41.7% against +17.5% for the S&P 500, dividends included.

HYPR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26HYPRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HYPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Hyperfine, Inc. (HYPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 85% of US stocks

Price / sales
5.1×

Cheaper than 25% of US stocks

Price / book
2.3×

Cheaper than 41% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
44.8%

Higher than 84% of US stocks

Earnings growth (YoY)
44.8%

Higher than 73% of US stocks

Gross margin
50.7%

Higher than 63% of US stocks

Operating margin
−216.9%

Higher than 10% of US stocks

Net margin
−210.8%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−97.0%

Higher than 14% of US stocks

Return on assets
−38.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Hyperfine, Inc. (HYPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Hyperfine, Inc. has a market value of $83.4M and an enterprise value of $53.7M.

  • Revenue in the twelve months to 30 June 2026: $16.5M. The latest quarter grew 44.8% year on year.

  • Net income over the same four quarters: −$34.9M, a −210.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.38.

  • Free cash flow in the twelve months to 30 June 2026: −$27.5M.

  • Shares outstanding: 106.0M.

  • Trailing P/E: −1.8×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Hyperfine, Inc. employs 102 people — $162K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

HYPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HYPRHyperfine, Inc.$83.4M
50
ECORelectroCore, Inc.$86.7M
59
SERASera Prognostics, Inc.$79.5M
41
LNSRLENSAR, Inc.$90.7M
62
LUNGPulmonx Corp.$76.3M
82
CVRXCVRx, Inc.$75.8M
33
MBOTMicrobot Medical, Inc.$97.4M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hyperfine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HYPR news & analysis

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

Business Wire · 31 Aug 2026neutral

Hyperfine, Inc. announced it will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10th, where management will host in-person meetings with investors.

Why it matters — The company's management will have direct in-person engagement with investors at a growth-focused conference, which could raise visibility for Hyperfine among the investment community.

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Business Wire · 26 Aug 2026positive

Hyperfine announced momentum from the first year of its neurology office launch, reporting peer-reviewed NEURO PMR results and more than 3,000 office-based brain MRI scans using its Swoop system across neurology practices.

Why it matters — The results and scan volume indicate growing clinical adoption of the Swoop system in neurology practices, a key part of Hyperfine's commercial expansion.

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Business Wire · 20 Aug 2026positive

Hyperfine announced FDA clearance of its next Optive AI software, which enhances image quality, clinical utility, ease of use, and isotropic imaging capability of its Swoop system across care settings.

Why it matters — A HYPR watcher would care because the FDA clearance strengthens the Swoop system's offering, potentially broadening its clinical and market applicability.

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Hyperfine, Inc.'s Q2 2026 earnings call, covering the company's quarterly results and management commentary.

Why it matters — A Hyperfine watcher would rely on this transcript for management's detailed discussion of the company's quarterly performance.

Hyperfine Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Hyperfine reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, in its Q2 earnings call. The portable MRI company attributed the growth to gains across hospital, neurology office, and international markets.

Why it matters — A 45% year-over-year revenue increase signals expanding adoption of Hyperfine's portable MRI across multiple market segments, which is a key indicator for HYPR watchers tracking the company's commercial momentum.

FAQ

Frequently asked questions about HYPR stock

What is the HYPR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Hyperfine, Inc. have a median 12-month price target of $2, with estimates ranging from $1.6 to $2.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HYPR stock a buy right now?

Of the 3 analysts covering Hyperfine, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hyperfine, Inc. 50 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HYPR?

As at 12 Sept 2026, Hyperfine, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will HYPR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +154.3% from the last close, and Ticker Nerd's factor model ranks Hyperfine, Inc. 50 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HYPR stock forecast for 2030?

No analyst covering Hyperfine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HYPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $2.5 over the next 12 months.

How has HYPR stock performed over the past year?

Hyperfine, Inc. returned -41.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Hyperfine, Inc. do?

Hyperfine, Inc. Class A Common Stock represents the equity of Hyperfine, Inc., a health technology and medical device company focused on portable magnetic resonance imaging.

What is the latest news on HYPR?

The most recent item we track (Business Wire, 31 Aug 2026): "Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference". Hyperfine, Inc. announced it will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10th, where management will host in-person meetings with investors.

Company

About Hyperfine, Inc.

Hyperfine, Inc. Class A Common Stock represents the equity of Hyperfine, Inc., a health technology and medical device company focused on portable magnetic resonance imaging. The company develops and commercializes the Swoop portable MR imaging system, which is designed to support brain imaging and clinical monitoring in settings where traditional MRI systems are less practical. Hyperfine also provides related support, maintenance, and technical services tied to its imaging products. Its offerings serve hospitals, intensive care units, stroke centers, and other medical facilities that use portable neuroimaging to help broaden access to diagnostic imaging. Based in Guilford, Connecticut, Hyperfine operates in the medical specialties segment of the health technology market, where it combines imaging hardware, software, and service capabilities around ultra-low-field MRI applications.

CEO Ms. Maria Degois-Sainz · 102 employees · United States · https://www.hyperfinemri.com